Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
April 2019
-
Key ReleaseNovartis entame 2019 avec une forte croissance des ventes et une hausse à deux chiffres du résultat opérationnel core[1], le lancement de Mayzent et le spin-off d'Alcon; profit annuel revu à la hausseLa transformation en une société axée sur les médicaments a continué avec le spin-off d'Alcon; les commentaires ci-après ne concernent que les activités poursuivies[2] Chiffre d'affaires net des…
-
Key ReleaseNovartis startet 2019 mit starken Umsätzen und einer zweistelligen Steigerung des operativen Kernergebnisses[1], Einführung von Mayzent sowie Abspaltung von Alcon; Gewinnprognose angehobenDie Transformation zu einem fokussierten Arzneimittelunternehmen schreitet mit der Abspaltung von Alcon voran; die folgenden Angaben beziehen sich auf die fortzuführenden Geschäftsbereiche[2]…
-
Media ReleaseAveXis data reinforce effectiveness of Zolgensma® in treating spinal muscular atrophy (SMA) Type 1Ph 3 STR1VE data show prolonged event-free survival, early and rapid increases in CHOP-INTEND and significant milestone achievement in SMA Type 1, consistent with START trial First-in-human…
-
Media ReleaseNovartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMDBy 2020, over 1.5 million people in the US are likely to have wet AMD, the leading cause of blindness in industrialized countries Filing is based on Phase III data from the HAWK and HARRIER…
-
Media ReleaseEurope-Africa partnership spearheads development of next-generation antimalarial drugThe European & Developing Countries Clinical Trials Partnership (EDCTP) grants EUR 10 million over five years to "WANECAM 2" a unique collaboration between antimalarial drug researchers in…
-
In The NewsHow to be a boss in an unbossed companyIn this interview, Novartis CEO Vas Narasimhan sits down with CNNMoney Switzerland’s Urs Gredig and shares why he thinks innovation should come from the bottom and how wearing jeans and no…
-
Media ReleaseSandoz drives differentiated portfolio with deal to commercialize new treatment for Opioid-Induced Constipation in key European countriesAgreement with Shionogi to commercialize Rizmoic® (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European markets Rizmoic® is an innovative medicine…
-
Counting on combos for complex liver diseases
The best treatment for multifaceted diseases like NASH may be combinations of drugs.
-
Featured NewsAlcon becomes a separately traded standalone company
On April 9, 2019 Alcon becomes a separately traded company. Novartis and Alcon are now positioned to capitalize on significant growth opportunities and focus resources on their respective businesses and strategic priorities.
-
Media ReleaseNovartis continues transformation into a leading medicines company with completion of the Alcon spin-offNovartis positioned for sustained growth, including plans to improve Innovative Medicines core margins into mid-30s by 2022 Novartis has a catalyst-rich pipeline with 10 potential blockbuster…
-
Bringing gene therapy into focus
Dr. Botond Roska says we should keep our eyes on gene therapy.
-
Media ReleaseNovartis updates on the migraine collaboration with AmgenBasel, April 4, 2019 - Novartis announced today that there is a legal dispute with Amgen regarding the collaboration agreements in the field of migraine. On April 2, 2019, Amgen issued a notice of…
Pagination
- ‹ Previous page
- 1
- …
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- …
- 152
- › Next page